NasdaqCM:ABEO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$130.9m

Last Updated

2021/07/26 00:13 UTC

Data Sources

Company Financials +

Executive Summary

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Abeona Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABEO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ABEO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

2.3%

ABEO

3.3%

US Biotechs

2.0%

US Market


1 Year Return

-54.5%

ABEO

23.6%

US Biotechs

39.1%

US Market

Return vs Industry: ABEO underperformed the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: ABEO underperformed the US Market which returned 39.1% over the past year.


Shareholder returns

ABEOIndustryMarket
7 Day2.3%3.3%2.0%
30 Day-22.5%2.1%1.6%
90 Day-23.4%4.7%3.5%
1 Year-54.5%-54.5%25.4%23.6%41.3%39.1%
3 Year-90.2%-90.2%15.5%10.4%64.0%53.8%
5 Year-51.3%-51.3%48.4%36.5%123.9%99.0%

Long-Term Price Volatility Vs. Market

How volatile is Abeona Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Abeona Therapeutics undervalued compared to its fair value and its price relative to the market?

1.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABEO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABEO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABEO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ABEO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABEO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABEO is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Abeona Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

52.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABEO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABEO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABEO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABEO's revenue (70.2% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: ABEO's revenue (70.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABEO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Abeona Therapeutics performed over the past 5 years?

-32.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABEO is currently unprofitable.

Growing Profit Margin: ABEO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABEO is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.

Accelerating Growth: Unable to compare ABEO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: ABEO has a negative Return on Equity (-55.17%), as it is currently unprofitable.


Financial Health

How is Abeona Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ABEO's short term assets ($88.6M) exceed its short term liabilities ($40.8M).

Long Term Liabilities: ABEO's short term assets ($88.6M) exceed its long term liabilities ($6.2M).


Debt to Equity History and Analysis

Debt Level: ABEO's debt to equity ratio (1.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ABEO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABEO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABEO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.4% each year


Dividend

What is Abeona Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Michael Amoroso (43 yo)

0.67

Tenure

US$1,737,947

Compensation

Mr. Michael Amoroso serves as President and Director at Abeona Therapeutics Inc. since March 19, 2021 and Chief Executive Officer since November 01, 2020. Mr. Amoroso served as Chief Operating Officer of A...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.74M) is above average for companies of similar size in the US market ($USD545.00K).

Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.


Leadership Team

Experienced Management: ABEO's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: ABEO's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.3%.


Top Shareholders

Company Information

Abeona Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Abeona Therapeutics Inc.
  • Ticker: ABEO
  • Exchange: NasdaqCM
  • Founded: 1974
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$130.859m
  • Shares outstanding: 99.89m
  • Website: https://www.abeonatherapeutics.com

Number of Employees


Location

  • Abeona Therapeutics Inc.
  • 1330 Avenue of the Americas
  • 33rd Floor
  • New York
  • New York
  • 10019
  • United States

Listings


Biography

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/26 00:13
End of Day Share Price2021/07/23 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.